ganglionic blocker

• PHASE2ACTIVE_NOT_RECRUITING
  Cardiac Changes in Early Parkinson's Disease: A Follow up StudyCedars-Sinai Medical Center · NCT04218968
• PHASE1TERMINATED
  Cardiovascular Effects of Angiotensin (1-7) in Essential HypertensionVanderbilt University · NCT02245230
• PHASE1ACTIVE_NOT_RECRUITING
  Role of Sympathetic Activity and Splanchnic Capacitance in HypertensionVanderbilt University · NCT02425566
• PHASE2COMPLETED
  Stellate Ganglion Block as Adjuvant Therapy to ca Channel BlockerAssiut University · NCT04100824
• PHASE2ACTIVE_NOT_RECRUITING
  Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)Michele Tagliati, MD · NCT03775096
• PHASE3UNKNOWN
  Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, MemantineWayne State University · NCT03858270

via ClinicalTrials.gov